The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment

被引：1
|
作者：
Grega, Dominik [1 ,2 ]
Kolar, Jozef [1 ]
机构：
[1] Masaryk Univ, Fac Pharm, Dept Appl Pharm, Brno, Czech Republic
[2] Masaryk Univ, Fac Pharm, Dept Appl Pharm, Palackeho Tr 1946-1, Brno 61242, Czech Republic
来源：
VALUE IN HEALTH REGIONAL ISSUES | 2024年 / 40卷
关键词：
direct costs; elasticity factor; friction period; indirect costs; loss of productivity; FRICTION-COST METHOD; QUALITY-OF-LIFE; PRODUCTIVITY; DISABILITY; ILLNESS; IMPACT; WORK;
D O I：
10.1016/j.vhri.2023.10.001
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Objectives: This article aimed to count and compare treatment's direct (only biological drugs) and indirect (loss of productivity) costs in patients with rheumatoid arthritis from 2019 to 2021.Methods: The friction cost approach was used to establish indirect costs. Elasticity factor values and friction period for the Slovak Republic from 2019 to 2021 were determined. Direct drug costs were calculated based on average prices from 2019 to 2021 and the number of dispensed medication packages.Results: The average productivity loss reached euro2984.54 in 2019, euro3338.46 in 2020, and euro3154.01 in 2021. Total indirect costs include productivity loss and sick pay, and from 2019 to 2021 came the values of euro8.4 million, euro10.1 million, and euro8.1 million, respectively. Conclusions: Indirect costs were almost 2.5 to 3 times lower than the biological and targeted treatment costs.
引用
收藏
页码：13 / 18
页数：6
相关论文
共 50 条
  • [11] Review of Published Literature Reporting Economic Burden of Treatment Switching in Rheumatoid Arthritis
    Taylor, Peter C.
    Antonova, Jenya
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 321 - 323
  • [12] Rheumatoid arthritis: biological drugs and risk of infection
    Dixon, William G.
    LANCET, 2015, 386 (9990): : 224 - 225
  • [13] Different effects of biological drugs in rheumatoid arthritis
    Atzeni, Fabiola
    Benucci, Maurizio
    Salli, Salvatore
    Bongiovanni, Sara
    Boccassini, Laura
    Sarzi-Puttini, Piercarlo
    AUTOIMMUNITY REVIEWS, 2013, 12 (05) : 575 - 579
  • [14] TREATMENT INTERRUPTION OF BIOLOGICAL DRUGS IN RHEUMATOID ARTHRITIS: AN ASSESSMENT OF CASE-REPORTS
    Wiens, A.
    Borba, H. H.
    Leonart, L.
    Ferreira, V
    Steimbach, L. M.
    Tonin, F. S.
    Araujo, A. G.
    Piazza, T.
    Pontarolo, R.
    VALUE IN HEALTH, 2017, 20 (09) : A935 - A935
  • [15] Non-clinical safety of new biological drugs for rheumatoid arthritis treatment
    Suzuki-Nishimura, T
    Asakura, W
    Watanabe, S
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 201P - 201P
  • [16] The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis
    Silverman, Stuart
    Dukes, Ellen M.
    Johnston, Stephen S.
    Brandenburg, Nancy A.
    Sadosky, Alesia
    Huse, Dan M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (04) : 829 - 840
  • [17] Quantifying the economic burden of productivity loss in rheumatoid arthritis
    Filipovic, Ivana
    Walker, David
    Forster, Fiona
    Curry, Alistair S.
    RHEUMATOLOGY, 2011, 50 (06) : 1083 - 1090
  • [18] A Clinical Update and Global Economic Burden of Rheumatoid Arthritis
    Fazal, Syed Ali
    Khan, Mohammad
    Nishi, Shamima E.
    Alam, Fahmida
    Zarin, Nowshin
    Bari, Mohammad T.
    Ashraf, Ghulam Md.
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2018, 18 (02) : 98 - 109
  • [19] New drugs for the treatment of rheumatoid arthritis
    Schuna, AA
    Megeff, C
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (03) : 225 - 234
  • [20] The burden of rheumatoid arthritis and access to treatment:: health burden and costs
    Lundkvist, J.
    Kastaeng, F.
    Kobelt, G.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2008, 8 (Suppl 2): : S49 - S60
12345